ArticleFrontiers in immunology2026
Cellular interaction of mycosis fungoides tumor cells changes from cytotoxic CD8+ T cells in plaques to B cells in tumors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mycosis Fungoides (MF) is characterized by the proliferation of malignant skin-homing memory CD4+ T cells. The disease typically follows an indolent course, progressing from plaques (scaly, erythematous skin lesions) in the early stages (Ia-Ib) to tumors (>IIb) in approximately one-third of cases. Although recent studies have explored cell phenotypes and counts of the tumor microenvironment (TME) in MF progression, spatial interactions between tumor and reactive cells remain poorly understood. Methods: We performed a comprehensive high-dimensional analysis of immune cell composition and cellular interactions across MF stages using a custom Imaging Mass Cytometry (IMC) panel to examine the spatial complexity of the MF TME. Results: Stage-specific changes in the TME included an increased percentage of cytotoxic CD8+ cells in plaques and an increased percentage of B cells and dendritic cells in tumors. With progression of disease shift in the spatial organization of the TME was observed, from CD8+ T cell-tumor cell and monocyte-CD4+ T cell interactions in plaques to B cell-tumor cell interactions in tumors. Discussion: A stage-dependent shift in interactions from anti-tumor immune responses to features consistent with immune evasion mechanisms has been observed with the progression of MF. These insights underscore the importance of spatial context in understanding MF progression and highlight therapeutic targets that could inform stage-specific (immune)therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.